ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

solriamfetol

Also written as “JZP-110”, “Solriamfetol” and “Solriamfetol 300 mg”.

Its studies are mostly in Narcolepsy · Attention Deficit Disorder with Hyperactivity · Sleep Apnea, Obstructive · Depressive Disorder, Major · Disorders of Excessive Somnolence, led by 4 companies.

Drug pageSolriamfetol: every studyAll 29 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Feb 25, 202122 company-led studies, 7 open or runningNext primary completion: Dec 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Axsome Therapeuticsits history only117 open or runningphase 4since Feb 25, 2021Feb 25, 2021Dec 2026phase 3 · NCT06413433
Jazz Pharmaceuticals90 open or runningphase 3since Jan 15, 2015Dec 2, 2011none ahead
Ignis Therapeutics (Suzhou)its history only10 open or runningphase 3since Sep 27, 2023Sep 27, 2023none ahead
Johnson & Johnsonits history only10 open or runningphase 2since Nov 17, 2003Nov 17, 2003none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Jazz Pharmaceuticals only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Dec 2, 2011First study: phase 2 study in NarcolepsyFirst studyNCT01485770 · 33 enrolled · United States
  2. Sep 5, 2012Phase 2 study in NarcolepsyNCT01681121 · 93 enrolled · United States
  3. Jan 15, 20154 phase 3 studiesNCT02348632, NCT02348619, NCT02348606 and 1 more
  4. Jun 10, 20162 phase 2 studiesNCT02806908, NCT02806895
  5. Dec 9, 2016Named solriamfetolINNProposed as its International Nonproprietary Name in WHO's List 116 · before, JZP-110
  6. Jan 23, 2017Phase 2 study in Disorders of Excessive SomnolenceNCT03037203 · 66 enrolled · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 9 Jazz Pharmaceuticals leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03037203Disorders of Excessive Somnolence · United States2CompletedAug 201866
NCT02806908Narcolepsy · Netherlands2CompletedMay 19, 201924
NCT02806895Sleep Apnea, Obstructive · Netherlands2CompletedMay 28, 201934
NCT02348632Narcolepsy · United States, Canada, Finland and more3CompletedDec 2017645
NCT02348619Sleep Apnea, Obstructive · United States, Finland, France and more3CompletedNov 2016174
NCT02348606Sleep Apnea, Obstructive · United States, Canada, France and more3CompletedDec 2016476
NCT02348593Narcolepsy · United States, Canada, Finland and more3CompletedFeb 2017239
NCT01681121Narcolepsy · United States2CompletedAug 201393
NCT01485770Narcolepsy · United States2CompletedMay 201233

How it is read

Names in the registry

  • “JZP-110”, 7 entries
  • “Solriamfetol”, 4 entries
  • “Solriamfetol 300 mg”, 4 entries
  • “Solriamfetol 150 mg”, 3 entries
  • “Solriamfetol Dose A”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.